Subpulmonary membrane: A rare cause of right ventricular outflow tract obstruction.

Subpulmonary membrane is a rare cause of right ventricular outflow tract (RVOT) obstruction, and only a few case reports exist with or without associated ventricular septal defect. We report a series of three cases with subpulmonary membrane causing RVOT obstruction. Two of these have been operated (the first case operated after unsuccessful attempt at balloon dilatation), and the third case is on follow-up at present.

Case series of coronary artery aneurysms after Everolimus eluting stent implantation and comparison with Sirolimus eluting stents.

BACKGROUND: Coronary artery aneurysms after drug eluting stents are rare. We present a case series of type II coronary aneurysms after implantation of Everolimus eluting stents including patients developing giant aneurysms with a toxic course. CASE PRESENTATION: Over a span of 3.5 years at our center 2572 patients were implanted Everolimus eluting stents out of which 4 patients developed coronary type II aneurysms an incidence of 0.00156 whereas 5838 patients were implanted Sirolimus eluting 2nd generation stents out of which 2 patients developed similar aneurysms with an incidence of 0.00034. The slight increase in incidence in Everolimus stents does not reach statistical significance (p = 0.054) and is limited by single centre non randomized study. We also propose a hypothesis that the slight increase in the incidence maybe due to allergy to Methacrylate present in Everolimus eluting Xience stent's primer which is absent in other Sirolimus eluting stents used at our center but that needs to be further investigated. We also found some patients who developed giant aneurysms including Left main aneurysms. In our series operative repair of these patients had better outcomes than covered stent deployment but larger trials maybe needed to confirm the same. CONCLUSIONS: Coronary artery aneurysms after stent implantation are rare but occasionally giant aneurysms are formed with a toxic course. The incidence and morphology of aneurysms after Everolimus and Sirolimus eluting stent deployment do not differ much.

Unusual Presentation of a Rapidly Progressive Coronary Artery Pseudoaneurysm after Drug Eluting Stent Placement.

Infected coronary artery aneurysm (CAA) is a rare complication of percutaneous coronary intervention (PCI) and is associated with high morbidity and mortality. The management of infected CAA is unclear and is based on the clinical and imaging features. We report an interesting case of a giant infected right CAA secondary to Pseudomonas aeruginosa within four weeks of a drug eluting stent (DES) implantation. Chronological analysis of the coronary angiograms and computed tomography coronary angiography revealed rapid progression in the size of the aneurysm from small to a giant CAA over a period of four weeks. Patient remained afebrile throughout the hospital stay without any signs of septicaemia. In view of the rapid progression in size, surgical aneurysmal ligation with distal revascularisation was done with good post-operative recovery. Afebrile presentation of an infected CAA is very rarely reported in the literature as in our case. Early diagnosis using multimodality imaging and immediate surgical intervention are the cornerstone in the management of giant infected CAAs.

Early hemodynamic performance of the Trifecta™ surgical bioprosthesis aortic valve in Indian patient population: 12 month outcomes of the EVEREST post-market study.

BACKGROUND: Indian patients undergoing surgical aortic valve replacement (SAVR) differ from western populations with respect to aortic annulus size and valve disease morphology. The purpose of this post-market, non-randomized observational study was to evaluate the early hemodynamic performance of the Trifecta™ bioprosthesis (Abbott, previously St. Jude Medical, Minneapolis, US) in an Indian patient population. METHODS: From January 2014 to September 2015, 100 patients (mean age 64.4 ± 7.1 years, 62% male) undergoing SAVR for valve disease (68% stenosis, 7% insufficiency, 25% mixed pathology) were enrolled across 10 centers in India. Patients implanted with a 19-27 mm Trifecta™ valve were eligible to participate and were prospectively followed for 12-months post-implantation. Echocardiographic hemodynamic performance was evaluated at pre-implant, pre-discharge and at 12-months by an independent core laboratory. Adverse events were adjudicated by the study sponsor. Functional status at 12-months was assessed according to NYHA classification. Continuous data was summarized using descriptive statistics (mean &standard deviation,) and categorical data was summarized using frequencies and percentages. RESULT: Ninety patients (mean age 64.5, 62.2% male) completed the 12-month follow up. Significant improvements in hemodynamic valve performance were reported in 81 patients with available echocardiographic data at 12 months. Compared to baseline at 12-month follow up visit, mean effective orifice area increased from 0.75cm2 to 1.61cm2 (p < 0.0001), mean pressure gradient reduced to 10.42 mmHg from 51.47 mmHg (p < 0.0001), cardiac output increased from 4.46 l/min to 4.85 l/min (P 0.9254). Compared to baseline, functional status improved by ≥1 NYHA class in 75% of patients at 12 months (95% Clopper-Pearson (Exact) confidence limit [64.6%, 83.6%]). No instances of early mortality (< 30 days from index procedure) or structural valve dysfunction were reported. CONCLUSION: In an Indian patient population, implantation of the Trifecta™ bioprosthesis is shown to be safe and associated with favorable early hemodynamic performance and improved functional status at 12 months. TRIAL REGISTRATION: The clinical study has been registered under Clinical Trial Registry-India ( http://www.ctri.nic.in ) and registration number is CTRI/2014/02/004434 registered on 25 February 2014 retrospectively registered.

Reduced left internal mammary artery blood flow on normal sternal retraction.

The left internal mammary artery is the conduit of choice for bypassing the left anterior descending artery. A 72-year-old man underwent off-pump triple-vessel coronary artery bypass. The left internal mammary artery was harvested with brisk blood flow from the distal artery on completion of harvesting, but normal sternal retraction with a Medtronic OctoBase retractor led to cessation of flow. A vein graft was utilized for the left anterior descending artery, and the internal mammary artery was grafted to the first diagonal branch. Computed tomography-angiography on postoperative day 5 demonstrated no possible cause of the reduced flow on sternal retraction.

Ruptured pulmonary artery aneurysm: a surgical emergency.

Idiopathic pulmonary artery aneurysm rupture was diagnosed in a 79-year-old man who presented with a dry cough. He was considered unlikely to tolerate extensive pulmonary artery reconstruction or lung resection; hence, he was salvaged by timely ligation of the distal pulmonary artery at the origin of the aneurysm.

Ruptured hydatid cyst with an unusual presentation.

Ruptured pulmonary hydatid cyst may sometimes cause complications like empyema, bronchopleural fistula, and collapsed lung. These complications may mislead the diagnosis and treatment if prior evidence of cyst has not been documented before rupture. We present a case of a young male who presented with complete collapse of left lung with pyopneumothorax and bronchopleural fistula which was misdiagnosed as pulmonary tuberculosis. He was referred to us from peripheral hospital for pneumonectomy when his condition did not improve after six months of antitubercular chemotherapy and intercostals drainage. On investigation, CT scan revealed significant pleural thickening and massive pneumothorax restricting lung expansion. Decortication of thickened parietal and visceral pleura revealed a ruptured hydatid endocyst, and repair of leaking bronchial openings in floor of probable site of rupture in left upper lobe helped in the complete expansion of the collapsed lung followed by uneventful recovery.

Early anticoagulation after mechanical valve implantation, and related complications.

BACKGROUND AND AIM OF THE STUDY: Anticoagulation is started soon after mechanical valve replacement as the risk of thromboembolic complications is especially high during the first six months after surgery. At present there is no consensus on the optimal protocol to prevent early thrombogenic complications, without increasing the risk of postoperative hemorrhagic events. Herein is presented a comparative analysis of the various anticoagulation protocols utilized at the authors' institution. METHODS: Between July 2001 and October 2006, a total of 503 patients underwent mechanical valve implantation at the authors' institution. The patients were allocated to three comparable groups, depending on the anticoagulation regime administered. Group A patients (n = 221) received only oral anticoagulation from the first postoperative day; group B patients (n = 159) received oral anticoagulation plus low-molecular weight heparin; and group C patients (n = 123) received unfractionated heparin within 12 h of surgery in addition to oral anticoagulation. RESULTS: At 48 h after surgery the mean postoperative drainage was 514.1 +/- 202 ml, 783.4 +/- 369.7 ml, and 718.4 +/- 305.5 ml in groups A, B and C, respectively. Two patients in group A, 12 in group B and nine in group C required the reinsertion of additional intercostal/pericardial drains for collections (p = 0.002). Twelve patients had tamponade (seven in group B, five in group C; p = 0.002), and nine (five in group B, four in group C) required re-exploration for excessive drainage at >48 h after surgery (p = 0.01). There were three incidents of valve thrombosis within the first postoperative six months (one in each group). Two of these patients had a suboptimal International Normalized Ratio (INR), while the third patient had an INR >5 with congestive heart failure with hepatic failure. All three were successfully thrombolyzed and recovered after initial ventilatory and inotropic support. The incidence of thromboembolic stroke was low in all groups. CONCLUSION: Early oral anticoagulation alone provides optimum anticoagulation and is associated with minimum complications. Early supplementation with heparin increases the risk of hemorrhagic complications but without reducing the thromboembolic risk.